FrancophonIA/ELRC3.0 huggingface dataset:
English: It will also provide an information pack for patients to explain the medicine's side effects, remind them of the need for adequate calcium and vitamin D supplementation, and when patients should contact their doctor.
Maltese: Se tipprovdi wkoll pakkett ta' informazzjoni għall-pazjenti, fejn jiġu spjegati l-effetti sekondarji tal-mediċina, tfakkarhom dwar il-ħtieġa ta' supplimenti adegwati ta' kalċju u ta' vitamina D, u meta l-pazjenti għandhom jikkuntattjaw lit-tabib tagħhom.
English: The CHMP decided that Aclasta's benefits are greater than its risks and recommended that it be given marketing authorisation.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' Aclasta huma akbar mir-riskji tiegħu u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: The second study compared Aclasta with placebo in 2,127 men and women with osteoporosis who had recently broken their hip, and looked at the number of fractures over up to five years.
Maltese: Bil-mod l-għadam jinsilet u jsir aktar fraġli, u għalhekk ikun aktar faċli li jkollu frattura.
English: For more information about treatment with Aclasta, read the Package Leaflet (also part of the EPAR).
Maltese: Għal aktar informazzjoni dwar il-kura b'Aclasta, aqra l-Fuljett ta' Tagħrif (parti wkoll mill-EPAR).
English: Aclasta must not be used in patients with severe kidney problems, hypocalcaemia (low blood calcium levels), or in pregnant or breastfeeding women.
Maltese: Fin-nisa, l-osteoporożi hija aktar komuni wara l-menopawża, meta l-livelli tal-ormon tan-nisa, lestroġenu, jaqgħu.
English: Packaging
Maltese: Pakkett
English: Strength Pharmaceutical Form Route of Administration
Maltese: Għamla Farmaċewtika
English: (Invented) name
Maltese: Isem Ivvintat
English: Solution: 5 ml (30 mg/ml) + Flushing solution 5ml
Maltese: Soluzzjoni: 5 ml (30 mg/ml) + Soluzzjoni għattlaħliħ 5 ml
English: 150 mg Solution for infusion
Maltese: 150 mg Soluzzjoni għal infużjoni
English: 2 vials + 1 vial
Maltese: 2 kunjetti + kunjett 1
English: Intracerebroventr icular use vial (glass)
Maltese: Użu intraċerebroventrik ulari kunjett (ħġieġ)
English: MA (EU) number
Maltese: Numru tal-MA (EU) Isem (ivvintat)
English: The full EPAR for Travatan can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: L-EPAR sħiħ ta' Travatan jista' jiġi kkonsultat fis-sit elettroniku tal-Aġenzija ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Travatan.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Travatan.
English: Other information about Travatan
Maltese: Informazzjoni oħra dwar Travatan
English: The active substance in Travatan, travoprost, is a prostaglandin analogue (a man-made copy of a prostaglandin, one of a group of substances naturally found in the body).
Maltese: Is-sustanza attiva fi Travatan, it-travoprost, hija analogu protaglandinu (kopja magħmula mill-bniedem tas-sustanza naturali, prostaglandinu.
English: Travatan has been studied in 1,989 adult patients in three main studies, lasting between six and 12 months.
Maltese: Travatan ġie studjat f'1,989 pazjent adult fi tliet studji prinċipali, li damu madwar sitt xhur u 12-il xahar.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Travatan on 27 November 2001.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Travatan fis-27 ta' Novembru 2001
English: Why has Travatan been approved?
Maltese: Għaliex ġie approvat Travatan?
English: Travatan was at least as effective as timolol and as effective as latanoprost in reducing intraocular pressure.
Maltese: Travatan kien effettiv mill-inqas daqs timolol kif ukoll daqs latanoprost fit-tnaqqis tal-pressjoni intraokulari.
English: What is the risk associated with Travatan?
Maltese: X'inhu r-riskju assoċjat ma' Travatan?
English: What is Travatan?
Maltese: X'inhu Travatan?
English: In addition, Travatan was compared with timolol in a fifth main study over 3 months, involving 152 children between 2 months and 18 years of age.
Maltese: Barra minn dan, Travatan tqabbel ma' timolol f'ħames studju ewlieni fuq tliet xhur, involva 152 tifel u tifla bejn xahrejn u tmintax-il sena.
English: Travatan is used to reduce intraocular pressure (pressure inside the eye).
Maltese: Travatan jintuża sabiex inaqqas il-pressjoni intraokulari (pressjoni ġewwa l-għajn).
English: Travatan is a clear eye drop solution that contains the active substance travoprost.
Maltese: Travatan hu soluzzjoni ċara għat-taqtir fl-għajnejn li fiha s-sustanza attiva travoprost.
English: All three studies compared travoprost with timolol, which is the standard treatment for glaucoma.
Maltese: It-tliet studji kollha qabblu lil travoprost ma' timolol, li huwa l-kura standard għall-glawkoma.
English: The most common side effects when using Travatan (seen in more than 1 patient in 10) are ocular hyperaemia (increased blood supply to the eye, leading to eye irritation and redness) and iris hyperpigmentation (darkening of the colour of the iris).
Maltese: L-effetti sekondarji l-aktar komuni meta jintuża Travatan (li dehru f'aktar minn pazjenti 1 minn 10) huma iperemija okulari (żieda tad-demm fl-għajn, li twassal għal irritazzjoni u ħmura fl-għajn) u iperpigmentazzjoni tal-ħabba tal-għajn (jiskura l-kulur tal-ħabba tal-għajn).
English: How has Travatan been studied?
Maltese: Kif ġie studjat Travatan?
English: The CHMP decided that Travatan's benefits are greater than its risks and recommended that it be given marketing authorisation.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' Travatan huma akbar mir-riskji tiegħu u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: For the full list of all side effects and restrictions with Travatan, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet irrapportati bi Travatan, ara l-fuljett ta' tagħrif.
English: This summary was last updated in 12-2014.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'12-2014.
English: One of the three trials also included a comparison with latanoprost (another prostaglandin analogue used for glaucoma).
Maltese: Wieħed mit-tliet provi inkluda wkoll tqabbil ma' latanoprost (analogu prostaglandinu ieħor użat għallglawkoma).
English: By lowering the pressure, Travatan reduces the risk of
Maltese: Peress li jbaxxi l-pressjoni, Travatan inaqqas ir-riskju ta' ħsara.
English: It is used in adults who have open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) and in adults with ocular hypertension (when the pressure in the eye is higher than normal).
Maltese: Dan jintuża f'adulti li għandhom glawkoma b'angolu miftuħ (marda li tgħolli l-pressjoni fl-għajn minħabba li l-fluwidi ma jkunux jistgħu joħorġu) u f'adulti b'ipertensjoni okulari (meta l-pressjoni fl-għajn tkun ogħla minnormal).
English: The combined treatment with Travatan plus timolol produced an additional decrease of intraocular pressure in patients who were not controlled with timolol alone.
Maltese: Il-kura kkombinata bi Travatan flimkien ma' timolol ipproduċiet tnaqqis addizzjonali filpressjoni intraokulari f'pażjenti li ma kinux ikkontrollati b'timolol biss.
English: A fourth study also compared the effectiveness of adding Travatan to treatment with timolol (427 patients, six-month duration).
Maltese: Ir-raba' studju qabbel ukoll l-effikaċja li jiżdied Travatan għall-kura b'timolol (427 pazjent, għal sitt xhur).
English: The dose is one drop of Travatan in the affected eye(s) once a day, preferably in the evening.
Maltese: Id-doża hija taqtira waħda ta' Travatan darba kuljum fl-għajn(għajnejn) affettwata(affettwati), preferibbilment filgħaxija.
English: It can also be used in children from two months of age who have ocular hypertension or childhood glaucoma.
Maltese: L-effetti sekondarji rrappurtati fit-tfal huma simili għal dawk li dehru fl-adulti.
English: In the eye, prostaglandins increase the drainage of the watery fluid (aqueous humour) out of the eyeball.
Maltese: Travatan jaġixxi bl-istess mod u jżid il-fluss tal-fluwidu 'l barra mill-għajn.
English: When intraocular pressure is raised, it causes damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Maltese: Meta l-pressjoni intraokulari togħla, hija tikkawża ħsara fir-retina (il-membrana sensittiva għad-dawl fuq in-naħa ta' wara tal-għajn) u lin-nerv ottiku li jibgħat is-sinjali mill-għajn għall-moħħ.
English: EU/1/15/994/001 Kengrexal
Maltese: EU/1/15/994/001 Kengrexal 50 mg Trab għal konċentrat għal soluzzjoni għallinjezzjoni/infużjoni
English: Pack size
Maltese: Kunjett
English: Intravenous use Vial (glass)
Maltese: Użu għal ġol-vini
English: It is used:
Maltese: Jintuża:
English: The full EPAR for Arzerra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The active substance in Arzerra, ofatumumab, is a monoclonal antibody.
Maltese: Is-sustanza attiva f'Arzerra, l-ofatumumab, hija antikorp monoklonali.
English: Other information about Arzerra
Maltese: Informazzjoni oħra dwar Arzerra
English: Refractory CLL
Maltese: CLL rifrattarja
English: Relapsed CLL
Maltese: CLL rikaduta
English: The most common side effects with Arzerra (seen in more than 1 patient in 10) are lower respiratory tract infection (infection of the lungs such as pneumonia), upper respiratory tract infection (nose and throat infection), neutropenia (low levels of neutrophils, a type of white blood cell), anaemia (low red blood cell counts), nausea (feeling sick), fever, rash, dyspnoea (difficulty breathing), cough, diarrhoea and tiredness.
Maltese: L-effetti sekondarji l-aktar komuni b'Arzerra (li dehru f'iktar minn pazjent wieħed minn kull 10) huma infezzjoni fin-naħa t'isfel tal-passaġġ respiratorju (infezzjoni tal-pulmuni bħal pulmonite), infezzjoni finnaħa ta' fuq tal-passaġġ respiratorju (infezzjoni fl-imnieħer u fil-griżmejn), newtropenja (livelli baxxi ta' newtrofili, tip ta' ċellola bajda tad-demm), anemija (numru baxx ta' ċelloli ħomor tad-demm), nawżja (dardir), deni, raxx, dispnea (diffikultà biex tieħu n-nifs), sogħla, diareja u għeja.
English: Why is Arzerra approved?
Maltese: Għaliex ġie approvat Arzerra?
English: This is a summary of the European Public Assessment Report (EPAR) for Arzerra.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Arzerra.
English: This was switched to a full marketing authorisation on 24 April 2015.
Maltese: Din l-awtorizzazzjoni għat-tqegħid fis-suq saret sħiħa fl-24 ta' April 2015.
English: In patients whose previous treatment with both fludarabine and alemtuzumab had failed, 49% (47 out of 95) responded to treatment with Arzerra.
Maltese: F'pazjenti li l-kura preċedenti tagħhom kemm bi fludarabin kif ukoll b'alemtuzumab ma kinitx irnexxiet, 49% (47 minn 95) irrispondew għall-kura b'Arzerra.
English: Because the number of patients with CLL is low, the disease is considered ‘rare', and Arzerra was designated an ‘orphan medicine' (a medicine used in rare diseases) on 7 November 2008.
Maltese: Minħabba li l-għadd ta' pazjenti b'CLL huwa wieħed baxx, il-marda hija kkunsidrata ‘rari' u fis-7 ta' Novembru 2008, Arzerra kien ikklassifikat bħala ‘mediċina orfni' (mediċina użata f'mard rari).
English: It is given using an infusion pump.
Maltese: Jingħata bl-użu ta' pompa ta' infużjoni.
English: Arzerra is a cancer medicine used to treat adults with chronic lymphocytic leukaemia (CLL), a cancer of a type of white blood cells called lymphocytes.
Maltese: Arzerra huwa mediċina kontra l-kanċer li tintuża biex tikkura adulti b'lewkimja limfoċitika kronika (CLL), kanċer ta' tip ta' ċelloli bojod tad-demm imsejħin limfoċiti.
English: Arzerra plus fludarabine and cyclophosphamide was effective at increasing progression-free survival, with patients living on average for 28.9 months without their disease getting worse, compared with 18.8 months in patients given fludarabine and cyclophosphamide alone.
Maltese: Arzerra flimkien ma' fludarabin u ċiklofosfamid kien effettiv fiż-żieda tassopravivenza mingħajr progressjoni, b'pazjenti li għexu medja ta' 28.9 xhur mingħajr ma l-marda tagħhom marret għall-agħar, meta mqabbla ma' 18.8 xhur f'pazjenti li ngħataw fludarabin u ċiklofosfamid waħidhom.
English: The European Commission granted a conditional marketing authorisation valid throughout the European Union for Arzerra on 19 April 2010.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni b'kondizzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Arzerra fid-19 ta' April 2010.
English: In 95 of these patients, the disease had not responded to both fludarabine and alemtuzumab, and in 112, treatment with fludarabine had failed but the patients had not been treated with alemtuzumab because this medicine was not suitable for them.
Maltese: F'95 minn dawn il-pazjenti, il-marda ma wrietx rispons kemm għal fludarabin kif ukoll għal alemtuzumab, u f'112-il pazjent il-kura bi fludarabin ma kinitx irnexxiet iżda l-pazjenti ma kinux ġew ikkurati b'alemtuzumab minħabba li l-mediċina ma kinitx adegwata għalihom.
English: Arzerra plus chlorambucil was effective at increasing progression-free survival (how long the patients lived without their disease getting worse), with patients living on average for 22.4 months without their disease getting worse, compared with 13.1 months in patients given chlorambucil alone.
Maltese: Arzerra flimkien ma' klorambuċil kien effettiv biex iżid is-sopravivenza mingħajr progressjoni (kemm idumu jgħixu l-pazjenti mingħajr ma l-marda tagħhom tmur għallagħar), b'pazjenti li għexu medja ta' 22.4 xhur mingħajr ma l-marda tagħhom marret għall-agħar, meta mqabbla ma' 13.1 xhur f'pazjenti li ngħataw klorambuċil waħdu.
English: • in previously untreated patients who cannot be treated with fludarabine; in these patients it is used together with chlorambucil or bendamustine (other cancer medicines);
Maltese: • f'pazjenti li ma kinux ikkurati qabel li ma jistgħux jiġu kkurati bi fludarabin; f'dawn il-pazjenti jintuża flimkien ma' klorambuċil jew bendamustin (mediċini oħra kontra l-kanċer)
English: One main study involving 447 previously untreated patients who could not be treated with fludarabinebased therapy compared a combination of Arzerra plus chlorambucil with chlorambucil given alone.
Maltese: Studju ewlieni wieħed li fih ħadu sehem 447 pazjent li ma kinux ikkurati qabel u li ma setgħux jiġu kkurati b'terapija bbażata fuq il-fludarabin qabbel kombinazzjoni ta' Arzerra flimkien ma' klorambuċil ma' klorambuċil mogħti waħdu.
English: As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval.
Maltese: Peress li l-kumpanija forniet l-informazzjoni addizzjonali meħtieġa, lawtorizzazzjoni ma baqgħetx b'kondizzjoni u saret sħiħa.
English: Ofatumumab has been designed to attach to a protein called CD20 that is found on the surface of lymphocytes, including the cancerous lymphocytes seen in CLL.
Maltese: L-ofatumumab tfasslet sabiex teħel mal-proteina msejħa CD20 li tinsab fil-wiċċ tal-limfoċiti, inklużi l-limfoċiti kanċeroġeni li jidhru fis-CLL.
English: What are the risks associated with Arzerra?
Maltese: X'inhuma r-riskji assoċjati ma' Arzerra?
English: Before each infusion, the patient receives medicines, such as a corticosteroid, an antihistamine and paracetamol, to help to prevent infusion reactions (such as rash, fever, allergic reactions and difficulty breathing).
Maltese: Qabel kull infużjoni, il-pazjent jirċievi mediċini, bħal kortikosterojde, antiħistamina u paraċetamol, sabiex ikunu evitati r-reazzjonijiet għall-infużjoni (bħal raxx, deni, reazzjonijiet allerġiċi u diffikultà fitteħid tan-nifs).
English: The response rate was slightly lower in patients whose treatment with fludarabine had failed but who were not suitable for treatment with alemtuzumab (43%).
Maltese: Ir-rata ta' rispons kienet kemxejn inqas f'pazjenti li fuqhom il-kura bi fludarabin ma kinitx irnexxiet iżda li ma kinux adegwati għal kura b'alemtuzumab (43%).
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Arzerra can also be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Maltese: ema.europa.eu/Find medicine/Human medicines/Rare disease designations Dan is-sommarju ġie aġġornat l-aħħar f'08-2017.
English: Arzerra has been investigated in one main study involving 223 patients with CLL whose disease had not responded to previous treatment.
Maltese: Arzerra ġie investigat fi studju prinċipali wieħed li fih ħadu sehem 223 pazjent b'CLL li l-marda tagħhom ma wrietx rispons għall-kura preċedenti.
English: Arzerra is available as a concentrate that is made up into a solution for infusion (drip) into a vein.
Maltese: Arzerra jiġi bħala konċentrat biex jitħallat f'soluzzjoni għal infużjoni (dripp) ġol-vina.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found in certain cells in the body.
Maltese: Antikorp monoklonali huwa antikorp (tip ta' proteina) li tfassal biex jagħraf u jeħel ma' struttura speċifika (imsejħa antiġenu) li tinstab f'ċerti ċelloli fil-ġisem.
English: For the full list of side effects and restrictions with Arzerra, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet kollha b'Arzerra, ara l-fuljett ta' tagħrif.
English: How does Arzerra work?
Maltese: Kif jaħdem Arzerra?
English: What measures are being taken to ensure the safe and effective use of Arzerra?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Arzerra?
English: One main study involving 365 patients whose cancer had come back compared the combination of Arzerra plus fludarabine and cyclophosphamide with fludarabine and cyclophosphamide used alone.
Maltese: Studju ewlieni wieħed li fih ħadu sehem 365 pazjent li l-kanċer tagħhom reġa' feġġ qabbel ilkombinazzjoni ta' Arzerra flimkien ma' fludarabin u ċiklofosfamid flimkien ma' fludarabin u ċiklofosfamid użat waħdu.
English: Av. Baix Llobregat, 3-5
Maltese: Baix Llobregat, 3-5
English: ATCvet code: QP52AA51.
Maltese: QP52AA51.
English: AT-1160 Wien
Maltese: AT-1160
English: Τηλ: +357-22-591918 info.activet@cytanet.com.cy
Maltese: Έγκωμη, Λευκωσία Τηλ: +357-22-591918 info.activet@cytanet.com.cy
English: Date of last renewal: 01/07/2010.
Maltese: Data tal-aħħar tiġdid: 01/07/2010.
English: Bayer Hungária Kft. HU-1123 Budapest Alkotás u. 50
Maltese: HU-1123 Budapest Alkotás u. 50
English: (mg)
Maltese: [kg]
English: București-Ploiești nr. 1A, sector 1, București 013681-RO Tel: +40 21 529 5900
Maltese: Sos. București-Ploiești nr. 1A, sector 1, București 013681-RO Tel: +40 21 529 5900
English: Bayer plc
Maltese: United Kingdom Bayer plc
English: Calcium hydrogen phosphate anhydrous Cellulose, microcrystalline Silica, colloidal anhydrous Croscarmellose sodium Magnesium stearate Povidone
Maltese: Calcium hydrogen phosphate anidru Cellulose, microcrystalline Silica, colloidal anidru Croscarmellose sodium Magnesium stearate Povidone
English: The symptoms were completely reversible.
Maltese: Is-sintomi kienu kompletament riversibbli.
English: Renal elimination predominates.
Maltese: Eliminazzjoni renali tippredomina.
English: Roundworms: Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme
Maltese: Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme
English: Animal Health Arne Jacobsens Allé 13 DK-2300 Köpenhamn S Danmark
Maltese: Animal Health Arne Jacobsens Allé 13 DK-2300
English: Method of administration
Maltese: Metodu t'amministrazzjoni
English: Animal Health Arne Jacobsens Allé 13 DK-2300 København S Tlf: +45 4523 5000
Maltese: Arne Jacobsens Allé 13 DK-2300 København S Tlf: +45 4523 5000
English: : +30 210 6800900-9 info@hellafarm.gr
Maltese: EL-15123 Μαρούσι - Αθήνα Τηλ.: +30 210 6800900-9 info@hellafarm.gr
English: 5.4 mg/ml butylhydroxyanisole (E320; as antioxidant)
Maltese: 5.4 mg/ml butylhydroxyanisole (E320; bħala antiossidant)
English: Emodepside is a substrate for P-glycoprotein.
Maltese: Emodepside huwa substrat għal p-glajkoprotejn.
English: Do not administer orally or parenterally.
Maltese: Tapplikax oralment jew parenteralment.
English: 12 pipettes 20 pipettes 40 pipettes
Maltese: 20 pipetta 40 pipetta
English: Tapeworms: Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis
Maltese: Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis
English: Renal excretion of metabolites predominates.
Maltese: Eliminazzjoni renali tal-metaboliti tippredomina.
English: Praziquantel
Maltese: Prazikwantel
English: The main metabolites are monohydroxycyclohexyl derivatives of praziquantel.
Maltese: Il-metaboliti prinċipali huma derivattivi monohydroxycyclohexyl tal-prazikwantel.
English: Αντρέα Μιαούλη 50 CY-2415 Έγκωμη, Λευκωσία
Maltese: Αντρέα Μιαούλη 50
English: SI-1000 Ljubljana Tel: +386 1 5814 400
Maltese: Ljubljana Tel: +386 1 5814 400
English: ORION PHARMA ELÄINLÄÄKKEET Tengströminkatu 8, PL/PB 425 FI-20101 Turku/Åbo
Maltese: ORION PHARMA ELÄINLÄÄKKEET Tengströminkatu 8, PL/PB 425
English: Pharmacotherapeutic group: therapeutic antiparasitic agent.
Maltese: Grupp farmako-terapewtiku: sustanza terapewtika kontra l-parassiti.
English: Volume (ml)
Maltese: Volum [ml]
English: Lot: {number}
Maltese: Lott {numru}
English: Incompatibilities: Not applicable.
Maltese: Inkompatibilitajiet:
English: België/Belgique/Belgien
Maltese: België/Belgique/Belgien Bayer SA-NV
English: Animal Health Al. Jerozolimskie 158
Maltese: Jerozolimskie 158
English: Echinococcus multilocularis (mature adult and immature) Echinococcus granulosus (mature adult and immature)
Maltese: Echinococcus multilocularis (adulti maturi, adulti immaturi ) Echinococcus granulosus (adulti maturi, adulti immaturi )
English: KVP Pharma + Veterinär Produkte GmbH Projensdorfer Str. 324
Maltese: KVP Pharma + Veterinär Produkte GmbH Projjensdorfer Str.
English: Toxascaris leonina (mature adult, immature adult and L4) Ancylostoma tubaeforme (mature adult, immature adult and L4)
Maltese: Toxascaris leonina (adulti maturi, adulti mmaturi u L4) Ancylostoma tubaeforme (adulti maturi, adulti mmaturi u L4)
English: [Single-dose pipettes]
Maltese: [Pipetti ta' doża waħda]
English: Lungworms: Aelurostrongylus abstrusus
Maltese: Aelurostrongylus abstrusus
English: Appropriate combination of volumes
Maltese: Agħżel volumi adattati
English: DE-51368 Leverkusen Germany
Maltese: 51368 Leverkusen
English: Rua da Quinta do Pinheiro, 5 PT-2794-003 Carnaxide Tel: +351 21 4172121
Maltese: PT-2794-003 Carnaxide Tel: +351 21 4172121
English: Volume Emodepside Praziquantel
Maltese: Volum Emodepsajd Prazikwantel
English: Bayer SA-NV
Maltese: Luxembourg/Luxemburg Bayer SA-NV
English: Praziquantel (mg/kg bw)
Maltese: Prazikwantel [mg/kg piż talġisem]
English: 0.35 ml, 0.70 ml and 1.12 ml per pipette Blister packs containing 2, 4, 12, 20, or 40 unit dose pipettes; 0.70 ml pipette only: additional blister pack containing 80 pipettes
Maltese: Folji li għandhom pipetta b´doża waħda ta' 2, 4, 12, 20 jew 40 unit; pipetti ta' 0.70 ml biss; folji oħra addizzjonali li fihom 80 pipetta
English: Toxocara canis (mature adult, immature adult, L4 and L3) Toxascaris leonina (mature adult, immature adult and L4) Ancylostoma caninum (mature adult and immature adult) Uncinaria stenocephala (mature adult and immature adult) Trichuris vulpis (mature adult, immature adult and L4)
Maltese: Toxocara canis (adulti maturi, adulti immaturi, L4 u L3) Toxascaris leonina (adulti maturi, adulti immaturi u L4) Ancylostoma caninum (adulti maturi, adulti immaturi u L4) Uncinaria stenocephala (adulti maturi, adulti immaturi) Trichuris vulpis (adulti maturi, adulti immaturi u L4)
English: Excipients:
Maltese: Pereżempju:
English: 10 tablets 24 tablets 50 tablets
Maltese: 10 pilloli 24 pillola 50 pillola